Critical Warnings & Restrictions In Canada (Patient Safety First)

Basic Ismo Information

• INN (International Nonproprietary Name): Monoket is the brand name; its INN is isosorbide mononitrate.
• Brand Names Available In Canada (English): Monoket, Ismo, Imdur and similar isosorbide mononitrate products are used internationally; confirm exact Canadian marketed brands and DIN with Health Canada or your local pharmacy.
• ATC Code: C01DA14.
• Forms & Dosages: Immediate‑release tablets 10 mg and 20 mg; extended‑release tablets commonly 40 mg, 50 mg and 60 mg; packaged in blisters or bottles (20, 28, 30, 60, 100 tablets) depending on supplier.
• Manufacturers In Canada (English): Global manufacturers include Bayer AG, Atno Pharmaceuticals LLC, Krewel‑Meuselbach GmbH and Zentiva; local Canadian manufacturers not specified—verify supplier on product label.
• Registration Status In Canada (English): Not specified in the provided dataset; confirm approvals and DIN via the Health Canada Drug Product Database.
• OTC / Rx Classification: Prescription Only (Rx) in major markets; product requires a valid prescription.

Patient safety matters first when starting isosorbide mononitrate (often called ismo or Monoket) for angina prevention.

Follow Health Canada guidance, talk with your prescriber and pharmacist, and check the Drug Product Database for a DIN before use.

Do not start therapy without a prescriber order and pharmacist counselling, and document allergies and current medicines for every pharmacy visit.

Absolute contraindications from the product information include hypersensitivity to isosorbide mononitrate, severe hypotension, acute circulatory failure, recent acute myocardial infarction with low filling pressures, cardiac tamponade or constrictive pericarditis, known severe anaemia, and concurrent use of PDE‑5 inhibitors (sildenafil, tadalafil, vardenafil).

• Contraindications: Hypersensitivity to nitrates; acute circulatory failure (shock); severe hypotension; acute MI with low filling pressures; cardiac tamponade or constrictive pericarditis; known severe anaemia; concurrent PDE‑5 inhibitor use.

Keep a checklist of emergency red flags and seek urgent care if any occur.

1. Syncope or fainting.
2. Worsening chest pain despite treatment.
3. Sudden severe lightheadedness or very low blood pressure symptoms.

Vulnerable groups needing special attention include older adults, pregnant or breastfeeding people, those with severe hepatic or renal impairment, and some Indigenous communities who experience a higher burden of cardiovascular disease.

Document allergies, carry the product label or DIN, and report suspected adverse events to Health Canada through Canada Vigilance.

Monitor blood pressure promptly during initiation and dose changes.

High-Risk Groups

Why does the elderly population need extra care with isosorbide mononitrate?

Older adults have increased fall risk from orthostatic hypotension and often take multiple medicines that interact.

Start at the lowest effective dose and review all medications with a pharmacist to reduce polypharmacy risks.

Pregnancy and breastfeeding data are limited for isosorbide mononitrate; avoid unless a specialist recommends use and documents informed consent.

For Indigenous health, acknowledge higher cardiovascular disease burden and prioritise culturally safe, shared decision‑making with community health workers where available.

• Monitoring Steps: Regular blood pressure checks, symptom diary (headache, dizziness, chest pain), and medication reconciliation at each refill.
• Involve family or caregivers when appropriate to support adherence and safety.
• Flag medication on primary care records and ensure bilingual labelling if needed.

Dose adjustments are clinical decisions and must be supervised by the prescriber.

Interaction With Activities (Driving, Machinery, Workplace Safety)

Dizziness, lightheadedness and syncope are common side effects that can impair driving or operation of heavy machinery.

Provincial occupational health and safety rules and criminal impairment laws require that people do not drive or perform safety‑sensitive tasks until they know how a medication affects them.

Employers and clinicians should consider temporary workplace accommodations during initiation or dose changes.

1. Test response at home after first doses and dose increases.
2. Avoid driving for 24–48 hours if dizziness occurs.
3. Report persistent lightheadedness or fainting to your prescriber immediately.
4. Carry a medication card listing isosorbide mononitrate and contraindicated drugs such as PDE‑5 inhibitors.

Safety‑Sensitive Work

Examples include public transit drivers, heavy equipment operators, commercial pilots and other roles where sudden impairment risks public safety.

Q&A — “Can I Drive After Taking It In Canada?”

Short answer: No until you know how it affects you.

If you experience dizziness, syncope or marked hypotension, do not drive and seek medical advice.

Follow provincial laws and employer policies and document symptoms with your pharmacist or prescriber.

Usage Basics For Canadians

The INN is isosorbide mononitrate, often prescribed as Monoket, Ismo or Imdur in international markets.

In Canada, confirm specific marketed brands and DIN via the Health Canada Drug Product Database before dispensing.

This medication is prescription‑only and requires a valid prescriber order for dispensing by community or online pharmacies.

Packaging varies by formulation: immediate‑release (IR) tablets 10 mg and 20 mg and extended‑release (ER) tablets 40 mg, 50 mg and 60 mg are commonly available in blister packs or bottles.

Confirm bilingual labelling and ensure the dispensed product matches the prescribed IR versus ER formulation to avoid dosing errors.

Present provincial drug plan details at the pharmacy to support coverage checks.

INN, Brand Names Available In Canada

The INN is isosorbide mononitrate and common international brands include Monoket, Ismo and Imdur.

Confirm exact Canadian‑market brands and DIN with the Health Canada Drug Product Database or your dispensing pharmacist.

Pharmacists should record brand and formulation (IR versus ER) on the prescription label.

Legal Classification Under Health Canada

Isosorbide mononitrate is prescription‑only in major markets and requires a valid prescription in Canada.

• How to obtain a prescription: family physician, cardiologist, telehealth service or urgent care clinic.
• Online pharmacies will require an e‑prescription and prescriber verification before shipping.

Canadian Dosing Guide

Typical dosing for angina prophylaxis starts at 20 mg once or twice daily for IR formulations, titrating up to 20–40 mg twice daily as needed.

Extended‑release regimens are commonly 40–60 mg once daily for steady control.

Always maintain a nitrate‑free interval of at least 10–12 hours per day to prevent tolerance.

• IR Regimen: 10–20 mg one or two times daily, spacing doses to allow a nitrate‑free interval.
• ER Regimen: 40–60 mg once daily, usually taken in the morning with a nitrate‑free period overnight.

1. Baseline blood pressure and heart rate measurement before starting.
2. Start at the lowest effective dose.
3. Reassess blood pressure and symptoms within 3–7 days of initiation or dose change.
4. Adjust dose with prescriber oversight and document for coverage adjudication.

Q&A — “What If I Miss A Dose Under My Provincial Drug Plan?”

If you miss a dose, take it as soon as you remember unless it is within four hours of the next scheduled dose; do not double doses.

If you have a coverage gap or no refill, contact your dispensing pharmacy—provincial plans such as Ontario Drug Benefit, BC PharmaCare or RAMQ may permit emergency repeats or exceptional access.

Standard Regimens

Standard regimens per product information include IR 10–20 mg once or twice daily and ER 40–60 mg once daily.

Adhere to the nitrate‑free interval and verify exact Health Canada‑approved dosing against the product monograph and DIN.

Adjustments For Comorbidities

In people with diabetes, monitor blood pressure closely because cardiovascular complications are more common in this group.

Consider fall prevention strategies and coordinate glycaemic and cardiovascular care between primary care and pharmacy.

• Renal/Hepatic Impairment: Use caution, monitor BP, consider lower starting dose for marked hepatic dysfunction.
• Elderly: Start low and monitor for orthostatic hypotension and falls.
• Polypharmacy: Review interacting medicines with the pharmacist.

Interaction Chart (Canadian Context)

The most critical interaction is with PDE‑5 inhibitors such as sildenafil, tadalafil and vardenafil—concomitant use can cause life‑threatening hypotension and is an absolute contraindication.

Other interactions include additive hypotension with other antihypertensives, some antidepressants and alcohol.

Food interactions: alcohol increases vasodilation and hypotensive risk; caffeine has minimal direct interaction but can mask fatigue.

If a significant interaction is suspected, sit or lie down immediately, measure blood pressure if possible, and seek urgent care for persistent hypotension or syncope.

Food And Drinks

Alcohol potentiates vasodilation and hypotension—advise abstinence or low intake while initiating therapy or changing dose.

Caffeine does not have a major pharmacokinetic interaction but may mask symptoms such as fatigue or lightheadedness; counsel patients to monitor their symptoms carefully.

Common Drug Conflicts

PDE‑5 inhibitors remain the highest‑risk interaction and must not be used with isosorbide mononitrate.

Use pharmacy software and the Health Canada Drug Product Database to screen interactions at dispensing.

User Reports & Trends In Canada

Patients commonly report nitrate headaches that often improve with time, initial dizziness and variable symptom relief for angina prevention.

Reports are more frequent among older adults and those taking multiple medications.

Anecdotal sources include community pharmacy counselling logs, provincial adverse event reports and online patient forums; these reports are useful for monitoring but are not a substitute for clinical evidence.

• Common Patient Themes: Nitrate headache, lightheadedness on standing, the need for a nitrate‑free interval, confusion between IR and ER dosing.
• Advice For Clinicians: Document patient‑reported outcomes at refill visits and report suspected adverse events to Canada Vigilance.

Nitrate Headache

A vasodilatory headache often seen early in therapy that may lessen with continued use or dose adjustment.

Tolerance

Loss of effect with continuous exposure unless a nitrate‑free interval of at least 10–12 hours is observed.

Pharmacists should provide an educational leaflet at first dispense and during refills, with bilingual material where applicable.

Canadian Patient Forums And Review Platforms

Patient platforms and provincial portals reveal trends but can contain misinformation; rely on verified sources like Heart and Stroke Foundation Canada and provincial health sites.

Encourage patients to ask their pharmacist for evidence‑based counselling rather than relying solely on forums.

Community Pharmacy Feedback

Community pharmacists report common confusion between IR and ER formulations leading to dosing errors and many questions about headache management and driving safety.

Standardised counselling scripts and consistent documentation at the pharmacy counter help reduce errors.

Access & Purchase Options

Isosorbide mononitrate requires a prescription and can be filled at national chains such as Shoppers Drug Mart, Rexall, London Drugs and Jean Coutu, as well as independent community pharmacies.

Legitimate Canadian online pharmacies require a valid prescription, verify the prescriber and ship within Canada; check provincial restrictions for remote prescribing and emergency supply rules.

Checklist For Patients When Purchasing: bring ID and health card, provide full medication history, inform the pharmacist about PDE‑5 inhibitor use, and ask about provincial coverage and prior authorizations.

Contact your provincial drug plan (Ontario Drug Benefit, BC PharmaCare, RAMQ) for coverage details and exceptional access processes.

Note: In this online pharmacy, ismo is dispensed only with a valid prescription and is shipped discreetly across Canada in standard delivery windows.

National Pharmacy Chains

Large pharmacy chains generally stock isosorbide mononitrate generics and branded products and provide consistent pharmacist counselling.

Ask about blister packaging options and request manufacturer details if needed for DIN verification.

Online Pharmacies In Canada & Provincial Restrictions

Legitimate Canadian online pharmacies verify prescribers and ship within Canada; international shipments may be restricted or delayed.

Always verify the pharmacy licence and consult your pharmacist for counselling after delivery.

Mechanism & Pharmacology

Isosorbide mononitrate is a nitrate vasodilator that acts as a nitric oxide donor, relaxing vascular smooth muscle and reducing myocardial oxygen demand to prevent angina.

IR formulations have faster onset and shorter duration, while ER formulations provide sustained plasma levels for once‑daily dosing.

Do not chew or crush ER tablets because that disrupts controlled release.

Vasodilation

Relaxation of blood vessels to lower cardiac workload.

Preload / Afterload

Reductions in preload lower cardiac oxygen demand; afterload effects also reduce work for the heart.

Tolerance

Reduced response over time that is mitigated with a nitrate‑free interval.

• Patient Counselling Points: Take exactly as prescribed, maintain a 10–12 hour nitrate‑free interval, avoid PDE‑5 inhibitors, report severe headaches or fainting.
• Clinical Monitoring: Record baseline BP and heart rate, monitor during titration, and keep a symptom diary for angina frequency and side effects.

Simplified Explanation (Patient-Friendly)

It widens blood vessels so the heart does not have to work as hard, which helps prevent chest pain.

The most common side effect is a headache that often improves over days to weeks.

Keep the nitrate‑free interval to keep the medicine working.

Clinical Terms

Clinicians should consult the product monograph and the Health Canada Drug Product Database for full pharmacokinetic, dosing and safety details, and record the DIN at prescribing and dispensing.

Indications & Off-Label Uses In Canada

The approved indication is long‑term prophylaxis of angina pectoris (stable angina) according to product information.

Isosorbide mononitrate is not intended for acute angina attacks—short‑acting nitroglycerin is the appropriate acute rescue medication.

Approved

Long‑term prevention of stable angina pectoris; verify exact labelled indications via the product monograph and DIN.

Off‑Label

Occasional specialist‑supervised use as an adjunct in select heart failure cases or refractory angina; requires cardiology oversight and documented rationale.

1. Prescribers should document the indication, monitoring plan and obtain informed consent for off‑label use.
2. Check the DIN and product monograph before prescribing for a non‑label indication.

Approved Indications (DIN)

Stable angina prophylaxis is the main approved use; verify the specific product’s DIN and monograph on the Health Canada Drug Product Database.

Common Off‑Label Practices

Canadian physicians may use isosorbide mononitrate selectively in heart failure or refractory angina under specialist supervision with monitoring and documentation.

Key Clinical Findings

Clinical evidence through 2022–2025 reaffirms efficacy for angina prophylaxis and highlights the need for a daily nitrate‑free interval to limit tolerance.

Pharmacovigilance trends reported to Canada Vigilance commonly include headaches and dizziness; serious hypotension is rare and usually associated with interactions such as PDE‑5 inhibitor co‑use or overdose.

• Efficacy: Effective for reducing angina frequency when used with appropriate dosing schedules and nitrate‑free intervals.
• Tolerance Risk: Continuous exposure without nitrate‑free interval reduces benefit; schedule a 10–12 hour gap daily.
• Adverse Events: Very common headache; common dizziness and flushing; rare severe hypotension linked to interactions.

Health Canada continues active safety monitoring and updates the product monograph as needed; report suspected adverse events promptly.

Canadian And International Studies 2022–2025

Recent studies have reinforced the clinical need for nitrate‑free intervals and documented real‑world tolerance patterns.

Refer complex or refractory cases to cardiology for multidisciplinary management.

Ongoing Health Canada Safety Monitoring

Clinicians and patients should report adverse events to Canada Vigilance and monitor Health Canada advisories and product monographs for updates.

Alternatives Matrix

When isosorbide mononitrate is unsuitable, alternatives include isosorbide dinitrate, nitroglycerin for acute attacks, nicorandil, ranolazine, beta‑blockers and calcium channel blockers.

Discuss pros and cons with the patient, including onset speed, dosing frequency, side‑effect profiles and provincial coverage.

Comparable Medicines With DIN In Canada

Check the Health Canada Drug Product Database for DINs of alternatives and review provincial formularies for reimbursement.

Typical alternatives to consider include isosorbide dinitrate, nitroglycerin, nicorandil, ranolazine, beta‑blockers and calcium channel blockers.

Pros And Cons Checklist

• Consider efficacy for the patient’s angina pattern and comorbidities.
• Review interaction profiles, especially PDE‑5 inhibitors contraindications.
• Assess patient ability to adhere to dosing schedules and nitrate‑free intervals.
• Check cost and provincial coverage before switching therapies.

Common Questions From Canadian Patients

Why do I get headaches?

Headaches are a common vasodilatory effect that often improves with continued use or dose adjustment.

Can I take PDE‑5 inhibitors?

No—concomitant use is an absolute contraindication because of the risk of severe hypotension.

How long before it works?

IR formulations act faster and can reduce angina frequency soon after titration; ER formulations reach steady state over days.

Is it covered by my provincial plan?

Coverage varies by province and plan; check your plan formulary and provide the DIN and diagnosis code for prior authorization if required.

• If you experience severe headache, try simple analgesia as advised by your pharmacist and report persistent severe symptoms.
• If you faint or have severe hypotension, seek emergency care immediately.
• Keep a one‑page bilingual handout summarising dosing, nitrate‑free intervals, interactions and emergency actions.

Coverage & Purchase Comparison Guidance

Create a comparison table for provincial plans showing coverage status, typical copays, required documentation and time to approval.

Checklist For Patients Seeking Coverage: collect recent prescription and diagnosis code, request pharmacist help for exceptional access, and consider manufacturer or generic options to reduce cost.

1. Obtain a valid prescription with DIN.
2. Verify provincial formulary listing and copay.
3. Ask pharmacist about emergency refill rules to avoid gaps.
4. Keep receipts for reimbursement claims.

Comparison Table — Province / Plan, Coverage Status, Typical Patient Cost, Prescription Required

Populate the live table with current provincial formulary data and link to official plan pages for accuracy at the point of care.

Step‑By‑Step Purchase Checklist For Canadian Patients

• Get a valid prescription from your prescriber.
• Verify the DIN and formulation (IR versus ER) with the pharmacist.
• Check your provincial plan for coverage or prior authorization needs.
• Plan refill timelines to avoid running out of medication.

Registration & Regulation

Health Canada evaluates safety and efficacy and assigns a Drug Identification Number (DIN) to marketed products.

Isosorbide mononitrate has ATC code C01DA14 and global approvals, but confirm local Canadian availability and DIN in the Drug Product Database.

DIN

Drug Identification Number used for claims, coverage and pharmacovigilance tracking.

Product Monograph

Authoritative source for dosing, contraindications and safety information—consult before prescribing.

1. Hospital pharmacies should ensure formulary listing, storage protocols and staff training on contraindications and interactions.
2. Manufacturers and prescribers must follow reporting obligations for adverse events.

Health Canada Approval

Check the Drug Product Database for current approvals, product monographs and safety updates, and include the DIN when reporting issues.

DIN Number And Labelling Requirements

DINs are essential for coverage claims and pharmacovigilance, and some labelling must be bilingual where applicable.

Pharmacists should maintain clear records that include the DIN and dispensed brand/formulation.

Storage & Handling

Store isosorbide mononitrate below 25°C (77°F) and protect from moisture and direct sunlight.

Avoid humid locations such as bathrooms; keep in original blister packs in a dry place, especially in coastal or high‑humidity regions.

For shipped orders, avoid exposing the medicine to extremes of heat or cold during transit; insulate packages in very cold winters.

• Keep in child‑resistant containers and label with dosing instructions.
• Do not crush or chew ER tablets.
• Dispose of expired medication through pharmacy take‑back programs.

Standard Canadian Household Conditions

Room temperature storage away from kitchen steam and bathroom humidity is best.

Pharmacists should advise on proper home storage at point of sale.

Cold‑Chain Requirements

No cold‑chain is required for isosorbide mononitrate; normal room temperature is acceptable.

Guidelines For Proper Use

Prescribers should document indication and DIN on the prescription and specify IR or ER formulation clearly.

Pharmacists should verify formulation, counsel on the 10–12 hour nitrate‑free interval, review interactions (no PDE‑5 inhibitors), and provide headache management tips.

1. Baseline Monitoring: BP and symptom diary before initiation.
2. Follow‑Up: Check BP and symptoms within one week of starting or changing dose.
3. Emergency Plan: For overdose or severe hypotension, seek immediate medical care—supportive measures may include fluids and vasopressors in hospital.

Institutional protocols should cover switching between IR and ER products, patient education materials in both official languages, and routine adverse event reporting to Canada Vigilance.

• Patient Do’s: Take as prescribed, maintain nitrate‑free interval, carry medication information card, report severe symptoms immediately.
• Patient Don’ts: Do not use PDE‑5 inhibitors while on isosorbide mononitrate, do not crush ER tablets, and do not stop abruptly without consulting your prescriber.

Refer to cardiology for refractory symptoms, complex comorbidity management or when considering off‑label use.

Delivery Across Canada (English)